Polar Asset Management Partners Inc. lifted its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 144.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 99,100 shares of the company's stock after acquiring an additional 58,600 shares during the quarter. Polar Asset Management Partners Inc. owned 0.20% of Mineralys Therapeutics worth $1,220,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of MLYS. BNP Paribas Financial Markets bought a new stake in shares of Mineralys Therapeutics during the 4th quarter worth $48,000. ProShare Advisors LLC acquired a new stake in shares of Mineralys Therapeutics in the fourth quarter worth $128,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Mineralys Therapeutics by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company's stock worth $130,000 after buying an additional 989 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in shares of Mineralys Therapeutics in the fourth quarter worth $145,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Mineralys Therapeutics in the fourth quarter worth $154,000. 84.46% of the stock is owned by institutional investors.
Insider Buying and Selling
In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the company's stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $12.06, for a total value of $129,729.42. Following the completion of the transaction, the chief financial officer now owns 215,340 shares of the company's stock, valued at $2,597,000.40. This represents a 4.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Samsara Biocapital Gp, Llc acquired 600,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was bought at an average price of $13.50 per share, for a total transaction of $8,100,000.00. Following the completion of the purchase, the insider now owns 5,674,916 shares in the company, valued at approximately $76,611,366. This trade represents a 11.82% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 104,579 shares of company stock valued at $1,534,353. Insiders own 25.56% of the company's stock.
Analyst Ratings Changes
Several brokerages have recently commented on MLYS. HC Wainwright reaffirmed a "buy" rating and issued a $42.00 target price on shares of Mineralys Therapeutics in a research report on Tuesday, May 13th. Wall Street Zen raised Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday. Guggenheim set a $48.00 target price on Mineralys Therapeutics and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Finally, The Goldman Sachs Group reduced their price objective on Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating for the company in a research report on Thursday, February 13th.
Read Our Latest Report on MLYS
Mineralys Therapeutics Stock Down 3.0%
Shares of NASDAQ:MLYS traded down $0.50 on Thursday, reaching $16.16. The company had a trading volume of 142,131 shares, compared to its average volume of 479,211. Mineralys Therapeutics, Inc. has a twelve month low of $8.24 and a twelve month high of $18.38. The stock has a 50-day moving average price of $14.44 and a 200 day moving average price of $12.53. The stock has a market capitalization of $1.05 billion, a P/E ratio of -4.43 and a beta of -0.30.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.23. On average, sell-side analysts predict that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.
About Mineralys Therapeutics
(
Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Further Reading
Before you consider Mineralys Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.
While Mineralys Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
